ArticleLipids in health and disease2026
Association of erythrocyte fatty acid profiles with the presence and rupture of intracranial aneurysms.
Article in Lipids in health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundRisk stratification for intracranial aneurysm (IA) rupture remains suboptimal. Disrupted lipid metabolism may contribute to IA development and rupture. As stable biomarkers of long-term lipid status, evaluation of erythrocyte fatty acids may aid in risk assessment, although their clinical relevance remains unclear.
methodsThis case‒control study included 175 participants (64 controls without IAs, 61 with unruptured IAs, and 50 with ruptured IAs) who were recruited in 2024. Twenty-two erythrocyte fatty acids were quantified by gas chromatography, and their associations with IA presence and rupture were assessed using logistic regression. Fatty acids associated with rupture were identified using least absolute shrinkage and selection operator (LASSO) regression and incorporated into established rupture risk models (PHASES, ELAPSS, and UCAS). Incremental discriminatory value was evaluated by comparing the change in the area under the receiver operating characteristic (ROC) curve (ΔAUC) using DeLong’s test. Validation was performed in an independent external cohort comprising 53 participants (27 with unruptured IAs and 26 with ruptured IAs).
resultsHigh erythrocyte levels of total n-3 polyunsaturated fatty acids (PUFAs) were associated with decreased IA risk (OR 0.28, 95% CI 0.17–0.46), whereas high levels of saturated fatty acids, monounsaturated fatty acids, n-6 PUFAs and trans fatty acids were associated with increased IA risk (all P < 0.01). Total n-3 PUFA (OR 0.57, 95% CI 0.36–0.91; P = 0.019) and n-6 PUFA (OR 1.81, 95% CI 1.14–2.87; P = 0.012) levels were also associated with rupture. Five key fatty acids identified by LASSO (C18:1, C20:2n-6, C20:4n-6, C20:5n-3, C22:6n-3) significantly improved rupture discrimination (ΔAUC 0.134–0.163; all P < 0.05). In the validation cohort, fatty acid integration similarly enhanced discrimination across all risk models (all P < 0.05).
conclusionsErythrocyte fatty acid profiles are associated with IA presence and rupture. Incorporation of these profiles into existing risk models has the potential to refine rupture risk prediction and inform individualized risk stratification, pending validation in prospective or longitudinal cohorts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.